You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease
|
|---|---|
| Published in |
Memórias do Instituto Oswaldo Cruz, July 2009
|
| DOI | 10.1590/s0074-02762009000900042 |
| Pubmed ID | |
| Authors |
J Antonio Marin-Neto, Anis Rassi, Alvaro Avezum, Antonio C Mattos, Anis Rassi, Carlos A Morillo, Sergio Sosa-Estani, Salim Yusuf |
| Abstract |
Among the pathophysiological derangements operating in the chronic phase of Chagas disease, parasite persistence is likely to constitute the main mechanism of myocardial injury in patients with chronic chagasic cardiomyopathy. The presence of Trypanosoma cruzi in the heart causes a low-grade, but relentless, inflammatory process and induces myocardial autoimmune injury. These facts suggest that trypanocidal therapy may positively impact the clinical course of patients with chronic Chagas heart disease. However, the experimental and clinical evidence currently available is insufficient to support the routine use of etiologic treatment in these patients. The BENEFIT project--Benznidazole Evaluation for Interrupting Trypanosomiasis--is an international, multicenter, double-blind, placebo-controlled trial of trypanocidal treatment with benznidazole in patients with chronic Chagas heart disease. This project is actually comprised of two studies. The pilot study investigates whether etiologic treatment significantly reduces parasite burden, as assessed by polymerase chain reaction-based techniques and also determines the safety and tolerability profile of the trypanocidal drug in this type of chagasic population. The full-scale study determines whether antitrypanosomal therapy with benznidazole reduces mortality and other major cardiovascular clinical outcomes in patients with chronic Chagas heart disease. |
Mendeley readers
The data shown below were compiled from readership statistics for 174 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 1% |
| Colombia | 1 | <1% |
| Chile | 1 | <1% |
| Germany | 1 | <1% |
| Mexico | 1 | <1% |
| Argentina | 1 | <1% |
| Unknown | 167 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 29 | 17% |
| Student > Master | 25 | 14% |
| Researcher | 23 | 13% |
| Student > Bachelor | 13 | 7% |
| Student > Doctoral Student | 12 | 7% |
| Other | 42 | 24% |
| Unknown | 30 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 28% |
| Agricultural and Biological Sciences | 31 | 18% |
| Immunology and Microbiology | 13 | 7% |
| Biochemistry, Genetics and Molecular Biology | 12 | 7% |
| Chemistry | 10 | 6% |
| Other | 19 | 11% |
| Unknown | 40 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 February 2016.
All research outputs
#1,497,568
of 25,373,627 outputs
Outputs from Memórias do Instituto Oswaldo Cruz
#24
of 1,502 outputs
Outputs of similar age
#4,515
of 122,772 outputs
Outputs of similar age from Memórias do Instituto Oswaldo Cruz
#1
of 138 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,502 research outputs from this source. They receive a mean Attention Score of 4.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,772 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 138 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.